[1]CurrentPatentAssignee:SYNTAPHARMACEUTICALSCORP.-WO2015/38649,2015,A1Locationinpatent:Paragraph001570
Title: A phase I study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumor malignancies and lymphomas.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20111101
Title: Clusterin inhibition using OGX-011 synergistically enhances Hsp90 inhibitor activity by suppressing the heat shock response in castrate-resistant prostate cancer.
Journal: Cancer research 20110901